

1-27-2022

Computational genomics in the era of precision medicine: Applications to variant analysis and gene therapy

Yung-Chun Wang

Washington University School of Medicine in St. Louis

Julie Choi

Washington University School of Medicine in St. Louis

Shujuan Zhao

Washington University School of Medicine in St. Louis

Mariam Khanfar

Washington University School of Medicine in St. Louis

Kuangying Yang

Washington University School of Medicine in St. Louis

See next page for additional authors

Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs

Recommended Citation

Wang, Yung-Chun; Choi, Julie; Zhao, Shujuan; Khanfar, Mariam; Yang, Kuangying; Fu, Po-Ying; Wrubel, Max; Yu, Xiaobing; Jin, Sheng Chih; and et al, "Computational genomics in the era of precision medicine: Applications to variant analysis and gene therapy." *Journal of personalized medicine*. 12,2. . (2022). https://digitalcommons.wustl.edu/open_access_pubs/11629

This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been accepted for inclusion in Open Access Publications by an authorized administrator of Digital Commons@Becker. For more information, please contact vanam@wustl.edu.

Authors

Yung-Chun Wang, Julie Choi, Shujuan Zhao, Mariam Khanfar, Kuangying Yang, Po-Ying Fu, Max Wrubel, Xiaobing Yu, Sheng Chih Jin, and et al

Review

Computational Genomics in the Era of Precision Medicine: Applications to Variant Analysis and Gene Therapy

Yung-Chun Wang ^{1,†}, Yuchang Wu ^{2,†}, Julie Choi ^{1,†}, Garrett Allington ^{3,4,†}, Shujuan Zhao ^{1,†}, Mariam Khanfar ^{1,†}, Kuangying Yang ^{1,†}, Po-Ying Fu ¹, Max Wrubel ¹, Xiaobing Yu ^{1,5}, Kedous Y. Mekbib ⁶, Jack Ocken ⁶, Hannah Smith ^{4,6}, John Shohfi ⁶, Kristopher T. Kahle ^{4,7,8,9}, Qiongshi Lu ^{2,*} and Sheng Chih Jin ^{1,10,*}

- ¹ Department of Genetics, School of Medicine, Washington University, St. Louis, MO 63110, USA; yung-chun@wustl.edu (Y.-C.W.); c.m.choi@wustl.edu (J.C.); shujuanzhao@wustl.edu (S.Z.); k.mariam@wustl.edu (M.K.); kuangyingyang@wustl.edu (K.Y.); fup@wustl.edu (P.-Y.F.); w.max@wustl.edu (M.W.); xiaobing@wustl.edu (X.Y.)
- ² Department of Biostatistics & Medical Informatics, University of Wisconsin-Madison, Madison, WI 53706, USA; ywu423@wisc.edu
- ³ Department of Pathology, Yale School of Medicine, New Haven, CT 06510, USA; garrett.allington@yale.edu
- ⁴ Department of Neurosurgery, Massachusetts General Hospital, Boston, MA 02114, USA; HSMITH20@mgh.harvard.edu (H.S.); kahle.kristopher@mgh.harvard.edu (K.T.K.)
- ⁵ Department of Computer Science & Engineering, Washington University, St. Louis, MO 63130, USA
- ⁶ Department of Neurosurgery, Yale University School of Medicine, New Haven, CT 06510, USA; kedous.mekbib@yale.edu (K.Y.M.); jack.ocken@yale.edu (J.O.); john.shohfi@yale.edu (J.S.)
- ⁷ Division of Genetics and Genomics, Boston Children's Hospital, Boston, MA 02115, USA
- ⁸ Departments of Pediatrics and Neurology, Harvard Medical School, Boston, MA 02115, USA
- ⁹ Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA
- ¹⁰ Department of Pediatrics, School of Medicine, Washington University, St. Louis, MO 63110, USA
- * Correspondence: qlu@biostat.wisc.edu (Q.L.); jin810@wustl.edu (S.C.J.)
- † These authors contributed equally to this work.



Citation: Wang, Y.-C.; Wu, Y.; Choi, J.; Allington, G.; Zhao, S.; Khanfar, M.; Yang, K.; Fu, P.-Y.; Wrubel, M.; Yu, X.; et al. Computational Genomics in the Era of Precision Medicine: Applications to Variant Analysis and Gene Therapy. *J. Pers. Med.* **2022**, *12*, 175. <https://doi.org/10.3390/jpm12020175>

Academic Editor: Greg Gibson

Received: 30 December 2021

Accepted: 24 January 2022

Published: 27 January 2022

Publisher's Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Copyright: © 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

Abstract: Rapid methodological advances in statistical and computational genomics have enabled researchers to better identify and interpret both rare and common variants responsible for complex human diseases. As we continue to see an expansion of these advances in the field, it is now imperative for researchers to understand the resources and methodologies available for various data types and study designs. In this review, we provide an overview of recent methods for identifying rare and common variants and understanding their roles in disease etiology. Additionally, we discuss the strategy, challenge, and promise of gene therapy. As computational and statistical approaches continue to improve, we will have an opportunity to translate human genetic findings into personalized health care.

Keywords: rare variant; common variant; statistical genetics; genomics; bioinformatics; gene therapy; precision medicine

1. Introduction

Over the past decade, genome sequencing technology has been one of the fastest growing fields in biomedical science. Thanks to the progress in sequencing automation, the cost of sequencing has dropped dramatically. As a result, an enormous amount of genomic data has been generated, providing an informative profiling of human genetic variations, disease-related mutations, and association between genotype and phenotype [1–4].

With the achievement of the Human Genome Project and the HapMap Project in the early 2000s, human genetic research in complex diseases started a new chapter: genome-wide association studies (GWAS). In 2005, a landmark GWAS found two single nucleotide polymorphisms (SNPs) associated with age-related macular degeneration [5]. Later, GWAS

identified many risk loci associated with diseases and traits, including coronary heart disease [6], obesity [7,8], type 2 diabetes [9], schizophrenia [10], and so forth. As of 11 November 2021, the NHGRI-EBI GWAS catalog has documented 5457 publications and 318,587 associations [11]. Although these associations have led to novel insights into the genetic architecture underlying numerous complex traits, individual common variants tend to have weak effect sizes, and all common variants only explain a moderate proportion of heritability [12]. This lingering gap of “missing heritability” suggests that rare variants (defined as those genetic variants with a population allele frequency less than 1%) that are difficult to detect by GWAS, and possibly the interplay between common and rare variants, may play a major role in complex disease etiology.

With rapid advances in DNA sequencing technologies, assessment of rare genetic variants in complex traits has become feasible. In particular, whole-exome sequencing (WES) and whole-genome sequencing (WGS) have gained popularity in recent studies on gene discovery. Herein, we review the recent analytical approaches for identifying disease-associated rare variants in population-based or family-based studies based on WES or WGS. We also discuss recent advances in common variant association analysis and polygenic risk score methods. Finally, we discuss how to translate genetic discovery into effective therapeutics or treatments. The flow diagram is illustrated in Figure 1.




Figure 1. Overview of base pairs-to-bedside approach. Advances in genomic analysis, precision medicine, and gene therapy allow for the genetic evaluation of sporadic and inherited variants in families and large cohorts. Further elucidation of genetic etiology and disease pathomechanisms through genomic and integrative multi-omics studies then catalyze the production of new therapeutic options such as gene therapy for patient care.

2. Rare Variant Analysis in Unrelated Individuals

A major challenge in rare variant analyses for complex traits is the limited statistical power to identify individual variant associations due to the low allele counts. For example, given a balanced case-control study of 3 K subjects (1.5 K cases vs. 1.5 K controls) at a type I error α of 5×10^{-8} and a relative risk of 3, the power to detect a variant with minor allele frequency (MAF) equal to 0.5% is around 0.05. To boost statistical power, most rare-variant association methods combine association signals across multiple rare variants in pre-defined variant sets (e.g., genes, genomic regions, pathways, and functional annotations) and generally assume the presence of multiple trait-associated variants in the same variant set [13]. We note several popular methods below.

The combined multivariate and collapsing (CMC) test is one of the first methods to empower rare variant association analysis by collapsing all rare variants into a single test [14]. A later study introduced the variable threshold (VT) method, which improves statistical power by dynamically selecting the optimal MAF cutoff that distinguishes causal rare variants from nonfunctional variants with higher allele frequencies [15]. The development of the sequence kernel association test (SKAT) is particularly important because it allows for the incorporation of covariates and can also consider rare variants with opposite effect directions [16]. Other methods for studying the rare variant associations, including the cohort allelic sums test (CAST) [17], weighted sum test (WST) [18], the kernel-based adaptive clustering method (KBAC) [19], the versatile gene-based association study (VEGAS) [20], the gene-based association test that uses extended Simes procedure (GATES) [21], the multivariate association analysis using score statistics (MAAUSS) [22], and multi-trait analysis of rare-variant associations (MTAR) [23], have since been developed with subtle nuance in their algorithms. A summary of these methods is shown in Table 1. We also note that study designs, inference algorithms, and statistical details of many approaches have been extensively reviewed by Lee et al. [24].

Table 1. Statistical approaches for population-based or family-based rare variant analyses.

Type	Methods	Strengths	Weaknesses	Ref.
Rare variant analysis in unrelated individuals	Combined Multivariate and Collapsing (CMC) test	- More powerful and robust for analyzing a set of rare variants than testing each variant individually	- Reduced power when the grouped variants have effects in opposite directions	[14]
	Variable Threshold (VT)	- Makes no assumption about the causal variant's allele frequency - Boosts power using functional annotations that give higher weights to functional variants	- Reduced power when the set of variants grouped together have effects in opposite directions - High computational burden for permutation test	[15]
	Sequence kernel association test (SKAT)	- Considers rare variants with opposite effect directions - Test statistics have a closed form approximation for their null distribution - Computationally efficient - Can adjust for covariates	- Less powerful when causal variants have the same effect direction	[16]
	Cohort allelic sums test (CAST)	- More powerful and robust for analyzing a set of rare variants than testing each variant individually	- Reduced power when the grouped variants have effects in opposite directions	[17]

Table 1. *Cont.*

Type	Methods	Strengths	Weaknesses	Ref.
	Weighted sum test (WST)	- Can account for linkage disequilibrium (LD) between variants	- Lower statistical power given few causal variants within a gene	[18]
	Kernel-based adaptive clustering method (KBAC)	- Has higher statistical power in the presence of variant interaction	- No closed form null distribution for test statistics - High computational burden	[19]
	Versatile gene-based association study (VEGAS)	- Only uses summary statistics as input - Can account for LD between variants	- Less powerful for detecting a large gene with many typed non-causal variants - High computational burden	[20]
	Gene-based association test that uses extended Simes procedure (GATES)	- Only uses summary statistics as input - Can account for LD between variants - Variants can have opposite effect directions - Computationally efficient	- Designed for genome-wide association studies (GWAS) and has lower power in rare variant analysis	[21]
	Multivariate Association Analysis using Score Statistics (MAAUS)	- Leverages multiple phenotypes to improve statistical power	- High computational burden	[22]
	Multi-trait analysis of rare-variant associations (MTAR)	- Improved statistical power in multi-trait multi-variant association analysis - Only uses summary statistics as input	- Relies on a concordant common and rare variant genetic correlation between traits	[23]
De novo variants analysis	DeNovoWEST	- Estimates positive predictive values of each DNV being pathogenic - Incorporates a gene-based weighting strategy	- Limited to exome	[4]
	Chimpanzee–human divergence model	- Estimates the relative locus-specific rates of DNVs	- Can only be applied to a selected candidate gene set	[25]
	denovolyzeR	- Adjusts for sequence depth and the divergences based on human–chimp differences - Does not require any control samples for comparison	- Relies on a pre-computed tabulation of the probability of DNVs arising in each gene - Limited to exome	[26]
Autosomal recessive variant analysis	Resampling-based statistical framework	- Leverages trio data to compare the observed number of recessive genotypes with the empirically estimated counts under the null - Accounts for confounding due to population stratification and consanguinity	- Limited to exome - Strong assumption that all subjects’ genotypes are independent	[27]

Table 1. *Cont.*

Type	Methods	Strengths	Weaknesses	Ref.
	Sampling the observed genotypes and phenotypes by chance	<ul style="list-style-type: none"> - Incorporates the probabilities of sampling the observed genotypes and phenotypes by chance - Incorporates the phenotypic similarity of patients with the same recessive candidate gene - Corrects for gene-specific levels of autozygosity - Takes account of population structure 	<ul style="list-style-type: none"> - Limited to exome - Requires systematic genotype and phenotype data on a known number of families - Difficult to perform when recording of phenotype terms is incomplete and inconsistent 	[28]
	The phased haplotypes-based framework	<ul style="list-style-type: none"> - Uses the phased haplotypes from unaffected parents to estimate the expected number of biallelic genotypes in affected probands - Accounts for the fact that some fraction of the variants expected by chance are actually causal 	<ul style="list-style-type: none"> - Limited to exome - Strong assumption that all subjects' genotypes are independent - Strong assumption of full penetrance of all genotypes 	[29]
Joint analysis of transmitted variants and DNVs	Transmission and de novo association test (TADA), extTADA	<ul style="list-style-type: none"> - TADA is the first method developed to jointly model de novo and transmitted mutations by a hierarchical Bayesian modeling framework - extTADA performs a Markov chain Monte Carlo for the Bayesian analysis 	<ul style="list-style-type: none"> - Both are limited to exome - Both cannot incorporate recessive genotypes and model across disease traits 	[30,31]
	TADA-Annotations (TADA-A)	<ul style="list-style-type: none"> - Can combine information on all DNVs in both coding and nearby non-coding regions across studies 	<ul style="list-style-type: none"> - Cannot incorporate transmitted variants 	[32]
	TADA-Recessive (TADA-R)	<ul style="list-style-type: none"> - Can integrate signals from DNVs, transmitted dominant, and transmitted recessive variants 	<ul style="list-style-type: none"> - Limited to exome 	[33]
	Multi-trait TADA (M-TADA)	<ul style="list-style-type: none"> - Can jointly analyze DNVs from multiple traits 	<ul style="list-style-type: none"> - Limited to exome - Cannot incorporate transmitted variants - Can only perform pair-wise comparison 	[34]
X-linked variant analysis	Various XCI modes integrated statistical approach	<ul style="list-style-type: none"> - Considers all X-linked processes (random, skewed, and escaped XCI) - Performs a permutation-based procedure to assess the significance with well-controlled type I error rate 	<ul style="list-style-type: none"> - Has lower power in the random or escaped XCI test - Cannot provide accurate effect size estimate in the escaped XCI model 	[35]
	1 and 2 degree-of-freedom tests for association	<ul style="list-style-type: none"> - Easy to implement using the contingency table approach 	<ul style="list-style-type: none"> - False assumption of equal phenotypic effects between males' hemizygotes and females' homozygotes - Does not consider nonrandom XCI and escape from XCI 	[36]

Table 1. *Cont.*

Type	Methods	Strengths	Weaknesses	Ref.
Digenic variant analysis	Distinct XCI processes combined using a modified Fisher’s method	<ul style="list-style-type: none"> - Considers all X-linked processes (random, skewed, and escaped XCI) - Is the most statistically efficient and not sensitive to the unknown biological models 	<ul style="list-style-type: none"> - Strong assumption that all subjects’ genotypes are independent - Cannot adjust for covariates 	[37]
	Sex-specific burden analyses	<ul style="list-style-type: none"> - Can estimate the fraction of probands attributable to rare X-linked variants 	<ul style="list-style-type: none"> - Strong assumption of a monogenic model with full penetrance - Wide confidence intervals for several key parameters 	[38]
	The genetic linkage method	<ul style="list-style-type: none"> - Takes account of phenocopies and reduced penetrance - Able to deal with allelic heterogeneity - Able to identify rare alleles that are present in small numbers of families 	<ul style="list-style-type: none"> - Requires pedigrees of related individuals (and parents’ samples) - Not suitable for common or complex-trait diseases - Unable to deal with high dimensional data and non-linear regression tests 	[39]
	The candidate gene approach	<ul style="list-style-type: none"> - Useful as the first step in exploring known pathways in complex diseases - Offers high statistical power and is computationally efficient 	<ul style="list-style-type: none"> - Subjective in the process of choosing specific candidate genes - Lack of replication studies - Relies on prior hypotheses about disease mechanisms - Unable to deal with high dimensional data and non-linear regression tests 	[40]
	Case-only study design	<ul style="list-style-type: none"> - No need for control recruitment - Improved statistical power compared to the case–control design - Less multiple-testing correction 	<ul style="list-style-type: none"> - Potential increase in type I error rate if the independence assumption is violated - Unable to deal with high dimensional data and non-linear regression tests 	[41]
	Random forests	<ul style="list-style-type: none"> - Broad applications in data mining and machine learning - Flexible and powerful statistical learning tools for analysis - Relatively fast and can handle big GWAS 	<ul style="list-style-type: none"> - Sensitive to insufficient training data, confounding effects, reproducibility, and accessibility - Potential slow-performing algorithm when dealing with large data set - Requires much computational power and resources 	[42]

Association analysis methods are ordered and grouped by different types of genetic variants. Each method for certain types of genetic variants is listed in middle column. The references are indicated in the last column.

3. Rare Variant Analysis for Family-Based Studies

Family-based association analysis has become increasingly popular in sequencing studies because it provides an opportunity to identify genetic variants that complement the findings in studies of unrelated individuals. The ability to determine whether genetic variants segregate with disease status within families helps distinguish causal variants from non-causal variants [43]. The trio-based study design makes it possible to distinguish between de novo variants (DNVs) and transmitted variants [44,45]. Finally, family-based designs can employ both between- and within-family comparisons in a two-step analysis

to increase statistical power while staying robust to population stratification and other confounding factors [46–49].

3.1. *De Novo Variant*

Spontaneously arising DNVs—those present in proband but absent in parents—play an important role in the pathogenesis of rare congenital diseases such as congenital heart disease [27,45,50,51]. On average, every subject carries one DNV affecting the protein-coding region of the genome [52,53]. However, modeling DNVs has proven to be challenging because DNVs are not distributed equally across the genome and the sequencing depth and distribution vary across sequencing platforms when combining samples from different cohorts.

Several nuanced approaches have been developed to address these issues (Table 1). The O’Roak study was the first to estimate the relative locus-specific rates of DNV by incorporating locus-specific transition, transversion, and indel rates, gene length, and a null expectation based on chimpanzee–human genome differences. However, one major limitation of this approach is that it can only be applied to a selected candidate gene set [25].

To overcome this limitation and more broadly estimate the mutation rates, Samocha et al. developed a de novo expectation model to quantify the mutation rates based on trinucleotide sequence contexts and functional annotations, while adjusting for sequence depth and the divergences based on human–chimp differences [54]. Importantly, this method does not require any control samples for comparison, but instead quantifies the enrichment of synonymous DNVs as a negative control group. Furthermore, this Poisson testing framework for DNV enrichment can yield high statistical power that is difficult to achieve in case–control analysis. An R package called “denovolyzeR” was developed to implement this statistical framework [26].

More recently, Kaplanis et al. developed a method named DeNovoWEST to detect gene-specific enrichments of damaging DNVs. DeNovoWEST is a simulation-based approach that scores all classes of variants on a unified, empirically estimated severity scale quantifying pathogenicity [4]. Compared with denovolyzeR, DeNovoWEST incorporates a gene-based weighting strategy derived from the deficit of protein truncating variants in the general population (e.g., pLI scores) [55]. In the future, incorporation of functional genomic information (e.g., gene expression in disease-relevant tissues) and other variant prioritization metrics may further improve the performance of risk gene identification.

3.2. *Autosomal Recessive Variant Analysis*

To analyze recessive variants that include both homozygous and compound heterozygous variants, a case–control burden test can be performed. However, the challenge in case–control analysis lies in the often distinct ethnic composition and variable degrees of consanguinity (i.e., marriage between closely related relatives) across study cohorts or between cases and controls. Further, it is difficult to establish genome-wide significant associations in case–control comparisons when studying ultra-rare recessive genotypes due to limited statistical power [27].

Several analytical strategies have been developed to address these issues (Table 1). Nadia et al. developed a statistical approach that incorporated the probabilities of sampling the observed genotypes and phenotypes by chance and applied it to a cohort of 4125 families with rare and genetically heterogeneous developmental disorders to identify four novel autosomal recessive disorders [28]. Another study, by Jin et al., developed a resampling-based statistical framework that leverages trio data to compare the observed number of recessive genotypes with the empirically estimated counts under the null. This approach enables a powerful enrichment test while accounting for confounding due to population stratification and consanguinity [27]. Using this approach, they found recessive variants are enriched in distinct biological pathways separate from those implicated by other forms of inheritance and demonstrated that consanguinity is a stronger driver of the recessive form of birth defects [27].

More recently, Martin et al. devised a new approach to use the phased haplotypes from unaffected parents to estimate the expected number of biallelic genotypes in affected probands. Despite methodological differences in these approaches, recent studies unequivocally suggested that recessive coding variants only account for a small proportion of patients with rare congenital disorders (in the range of 1–4%), compared with 10–20% explained by coding DNVs [27–29]. The large proportion of unexplained patients even amongst those with affected siblings or high consanguinity suggests that complex inheritance (e.g., oligogenic and polygenic inheritance, gene–environment interaction) or other genetic variations (e.g., non-coding regulatory elements or structural variants) await discoveries using improved genomic technologies and statistical methods in the future.

3.3. Joint Analysis of Transmitted Variants and DNVs

Recent sequencing-based studies have revealed that disease risk genes could be affected by multiple types of genetic variations (e.g., DNVs, transmitted rare variants, or regulatory variants) [27,44,56]. To accelerate risk gene discovery, several groups have developed a novel statistical framework, known as the Transmission and De novo Association (TADA) test, to combine information from multiple types of genetic variations or across multiple genetically correlated disease phenotypes (Table 1). While these tools have been proven effective, there are some differences and limitations of each TADA variation. We provide a brief overview below.

The original TADA approach and an extended approach, extTADA, were designed to incorporate DNVs and transmitted dominant variants in proband–parent trios, as well as variants identified in unrelated cases and controls for risk gene mapping. A hierarchical Bayesian strategy is used to rank and test risk genes for a disease of interest [30,31]. However, these approaches fail to consider variants in the non-coding genome. Liu et al. employed an approach called TADA-Annotations (TADA-A), which combines information of all DNVs of a gene in both coding and nearby non-coding regions to maximize the power to detect risk genes [32]. The authors applied TADA-A to WGS data of ~300 ASD family trios and found that the contribution of de novo non-coding mutations could be comparable to that of de novo loss-of-function or missense mutations in the coding regions, which suggests that incorporation of non-coding variants from WGS data can aid risk gene discovery.

Another limitation of the original TADA approach is that it does not consider the contribution from recessive variants. This limitation has been addressed by TADA-Recessive (TADA-R), which is built upon TADA to include DNVs, autosomal dominant variants, and autosomal recessive variants [33]. By applying TADA-R to 2645 congenital heart disease-affected family trios, Li et al. identified 15 significant genes, half of which are novel, leading to new insights into the genetic basis of congenital heart disease and once again highlighting the importance of including recessive variants in genetic studies [33].

The development of multi-trait TADA (mTADA) coincided with the need for the ability to perform a joint analysis of DNVs from multiple genetically correlated disease traits to increase the statistical power for risk gene discovery [34]. The mTADA approach uses the expectation–maximization algorithm to draw associations between the two diseases. By applying mTADA to large datasets consisting of more than 13,000 trios for five correlated neuropsychiatric disorders and congenital heart disease, the authors reported additional risk genes and provided new insights into the shared and disorder-specific biological mechanisms across these disorders [34].

4. X-Linked Variant Analysis

The sex chromosome constitution is one major source of genetic variation in humans [57]. Moreover, there are many differences in the phenotypes between females, who typically have two X chromosomes, and males, who typically have one X and one Y chromosome. However, the impact of genetic variations on the sex chromosomes has been largely overlooked in genetic association studies. Additionally, the complex and dynamic X

chromosome inactivation (XCI) creates challenges in X-linked variant analyses [35,58]. XCI, as first described by Ohno et al. in 1959, usually occurs randomly for one of the two X chromosomes in females to equalize dosage of gene products from the X chromosomes between males and females [59]. Conventional approaches for X-linked variant analysis, such as the Cochran–Armitage test, assume equal phenotypic effects between males' hemizygotes and females' homozygotes (Table 1) [36]. However, recent studies showed that genes on the silenced X chromosome can be nonrandomly selected for inactivation and some can escape from XCI [35,60,61]. Thus, the contingency table approach could lead to a significant power loss if the underlying biological mechanisms are nonrandom or escaped XCI.

To address this, Wang et al. took various XCI modes (i.e., random, nonrandom, or escaped XCI) into consideration, and proposed a new statistical approach with greater statistical power in which 0 or 2 were used for genotype coding in males and 0, d, or 2 were used in females. Here, d quantifies females' heterogeneous effective allele counts (Table 1) [35]. Although the improved efficiency and robustness of this approach are suitable for genome-wide analysis, this method did not consider linkage disequilibrium (LD) and lacked the ability to adjust for covariates such as age, which is likely to affect the XCI ratio [37,62,63].

The recent development of very large WES cohorts such as the Deciphering Developmental Disorders project, coupled with the improved understanding of the germline mutation rate, have enabled more robust estimation of the absolute and relative fraction of inherited variants and DNVs for complex diseases. Martin et al. conducted sex-specific burden analyses of damaging DNVs to identify an enrichment of specific classes of X-linked variants in probands and estimated the fraction of probands attributable to those variants [38]. They found that such variants do not fully account for the differential prevalence between the sexes and that the bulk of X-linked burden is in known developmental disorder-associated genes [38]. More robust X-linked variant analysis and better understanding of sex differences in X chromosome biology will require even larger cohorts and integration of multi-omics data (e.g., RNA-seq or ATAC-seq) that can suggest which X chromosome is silenced and to what degree a gene is expressed on the inactivated X chromosome.

5. Digenic Variant Analysis

Digenic inheritance (DI) refers to the simplest form of oligogenic inheritance [64]. Individuals with digenic diseases harbor two risk variants at two genomic loci that correspond to the development of phenotypes that do not segregate in the typical Mendelian inheritance fashion. While thousands of variants have been discovered and linked to monogenic diseases, only a few hundred were linked to 54 digenic disorders according to the DIDA database (<http://dida.ibsquared.be/>, accessed on 17 November 2021). This can be attributed to several factors, including difficulties in establishing a genotype–phenotype correlation, reduced penetrance, phenotypic and expression variability, and most importantly, the lack of efficient and robust methods for detecting gene–gene interaction due to the overall small effect of each variant on disease risk. The genetic linkage analysis method was successful in detecting digenic diseases in some families [39], but other methods can be used specially when the parents' samples are not available for segregation analysis (Table 1). For example, the candidate gene approach was very useful in some cases where a gene of interest is selected to be investigated based on its relevance to the pathway(s) involved in the development of the disease [40]. The approach is quick, cheap, and offers high statistical power. However, it has been faced with criticisms due to the lack of replication studies and how much is known about the biological aspect of the investigated disease [65]. Nowadays, the case-only and machine learning approaches are heavily and continuously developed for the prediction of digenic diseases.

5.1. Case-Only Approach

The case-only design provides an estimation of gene–gene interactions without requiring negative control samples [66] and demonstrates improved statistical power compared to

the case–control design [67,68]. Recently, Kerner et al. proposed a genome-wide, case-only study based on WES data [41]. This approach uses each gene as the unit of analysis and tests all pairs of genes to detect gene-pair interactions underlying diseases. Furthermore, Kerner et al. used a classic variant aggregation approach to combine multiple variants within a gene, and the CAST approach was used to perform burden tests, allowing for further improved statistical power. The proposed method appears to be simple and flexible to apply, with a major advantage of the eliminated need for control recruitment. Moreover, performing hypothesis testing at the gene level greatly reduces the burden of multiple testing and computational time. However, this approach is not robust to gene–gene correlation (e.g., variants in LD) and will have substantially inflated type I error if the independence assumption is violated.

5.2. Machine Learning

Although the aforementioned methods have contributed significantly to unraveling oligogenic diseases, they are often met with limitations and criticism, predominantly due to their inability to deal with high dimensional data and non-linear regression tests. For these reasons, machine learning methods started to gain recognition and popularity in the field of genetics, particularly supervised machine learning where the algorithm predicts potential gene–gene interaction as an output depending on the input data and the set of rules obtained through model training. Among the supervised machine learning models, random forests (RFs), neural networks, cellular automata, and multifactor dimensionality reduction are the most used [69]. RFs, a tree-based ensemble approach with several decision-tree classifiers, is especially popular in the field. Where each tree in the forest is trained with a set of data to predict the outcome, in this context the RFs algorithm would predict the gene–gene interaction causing the phenotype in question [42]. The Oligogenic Resource for Variant AnaLysis (ORVAL), which has been used to study digenic diseases, is also a popular online platform that integrates innovative machine learning methods for combinatorial variant pathogenicity prediction with visualization techniques [70–73]. The candidate digenic predictions are then used to rank gene pairs and build an interactive oligogenic network that can be further explored.

It is understandable that traditional methods alone are unable to detect digenic variants due to the limitations imposed by the used statistical tests and the often-required pre-knowledge of biological aspects of diseases. Likewise, limitations can be faced with the machine learning approach due to insufficient training data, confounding effects, reproducibility and accessibility, and the potential slow-performing algorithm when dealing with large data sets [74,75]. Furthermore, the lack of large case–control cohorts hinders the chances of conforming causative genetic variant combinations. Recent studies on oligogenic diseases provide evidence of the crucial need to combine genetic analysis methods along with functional and experimental studies for validation. Li et al. have provided the first experimental evidence of oligogenic inheritance in heterotaxy, using sequencing analysis and functional studies on zebrafish and mouse [76]. Additionally, Gifford et al. published interesting findings of a family with affected children suffering left ventricular non-compaction cardiomyopathy (LVNC) [77]. In their study, affected children were found to harbor three genetic variants that were proven to cause LVNC when combined all together. CRISPR-Cas9 technology and human induced pluripotent stem cells were used for validation. This suggests that traditional methods alone are not efficient to detect or confirm the subtle effect of combined genetic variants, and that the use of advanced gene-editing coupled with in vivo/in vitro approaches is necessary in future diagnosis of oligogenic diseases.

6. Common Variant Association Analysis

A GWAS aims to identify associations between (typically millions of) SNPs and a disease or trait of interest. SNP genotypes are usually obtained using a genotyping microarray for a set of pre-determined variants. The genotype information for each bi-

allelic SNP is stored as the count of a reference allele, which can be coded as 0, 1, or 2. It is also a common practice to impute relatively common but ungenotyped SNPs based on a population haplotype reference panel [78]. A GWAS performs a genome-wide scan looking for SNPs that are significantly associated with the trait of interest while adjusting for covariates such as sex, age, and genetic principal components. Due to the large number of tests in GWAS, the convention is to use a stringent p -value threshold of 5×10^{-8} to account for multiple testing correction. Different from sequencing-based studies, a GWAS typically has a larger sample size due to the lower cost of microarray genotyping, but it is better powered to examine common variant associations than those for variants with lower frequencies due to poor imputation quality of rare variants, and a lack of ability for common variants to tag rare variants through LD.

Despite the simplicity, GWAS have identified tens of thousands of associations for numerous diseases and traits [79]. In particular, the recent emergence of large population-based biobanks (e.g., UK Biobank [1]) with comprehensive genotype and phenotype data, coupled with meta-analysis techniques [80] that allow a combination of summary-level association results across multiple independent cohorts, provides a golden opportunity for human geneticists to investigate the genetic basis of many human traits. It has been shown that GWAS-informed genes for disease traits are more likely to be drug targets [81]. Polygenic risk scores (PRS) based on large GWAS have shown substantially improved prediction accuracy and may have great potential for applications in the clinical setting [82].

GWAS also has some inherent limitations. One major challenge in population-based GWAS is the unadjusted confounding due to population stratification where different ancestry groups differ in both variant allele frequencies and the trait under study. In addition, recent evidence suggests that parental genotypes can be a major confounder for genetic associations identified in GWAS [83]. A person's genetic variants exist in both himself/herself and the biological parents. Thus, these variants can affect a person's phenotype both directly (through the inherited genetic variants) and indirectly (through the parents and the environment they create). GWAS results from a population cohort are a mixture of both the direct and indirect effects [84]. Because of these limitations, family-based GWAS, which investigate genotype–phenotype associations within families (e.g., between siblings), have gained renewed popularity [85]. Within-family GWAS is more robust to population stratification compared to studies conducted on unrelated individuals. Leveraging family data with shared environment also improves estimation of direct and indirect genetic effects, which provides more complete insights into the genetic basis of human complex traits [85,86]. However, statistical power remains moderate in family-based GWAS due to the limited number of families even in large biobanks.

Since the proportion of complex trait variance explained by the additive genetic components in GWAS is often smaller than heritability estimated from twin studies, gene–gene interactions have been hypothesized to partially account for this discrepancy [87,88]. However, testing all pairwise (or higher order) SNP interactions is computationally challenging and will severely reduce statistical power. Additionally, recent studies suggested very limited evidence for common SNP epistasis in complex trait genetics [89,90]. However, a growing literature suggests that both common and rare variants contribute to the risk of many diseases, and there may be a polygenic background for even rare “Mendelian-type” diseases [91,92]. For example, numerous genes harboring rare pathogenic variants as well as intergenic regulatory SNPs with higher frequencies have been implicated in diseases such as congenital heart disease and ASD [27,93–97]. It remains an open question whether the common, potentially polygenic genetic background can explain the incomplete penetrance of rare causal variants [98,99]. Increasing samples of WGS data in population biobanks (e.g., UK Biobank and All of Us) as well as ascertained disease cohorts (e.g., Simons Simplex Collection) will provide new opportunities for studying how common and rare variants jointly shape complex human phenotypes [100].

7. Disease Risk Prediction

A key goal in human genetic research is to identify individuals at higher disease risks for early screening and intervention. Thanks to the widely accessible summary-level data from GWAS, PRS models that can be trained directly using GWAS summary statistics have quickly gained popularity in recent years. In a nutshell, a PRS is a weighted (by variant effect sizes) sum of risk allele counts across a (possibly large) number of SNPs. It quantifies the genetic predisposition of disease risk for an individual and thus can be used to stratify individuals into high and low risk groups [82].

Methodological challenges in computing PRS reside in estimating the highly polygenic yet typically weak SNP effects for most complex traits and accounting for extensive LD in the human genome. Recently, penalized regression models that re-estimate SNP effects from GWAS summary statistics while explicitly modeling LD have been shown to effectively improve the predictive performance of PRS [101–103], and novel resampling approaches now allow model fine-tuning without individual-level genotype and phenotype data [104]. Additionally, Khera et al. convincingly demonstrated that individuals with very high PRS show substantially elevated coronary artery disease risk that is comparable to having monogenic mutations with large effects [105]. These studies showcase a promising future for PRS application in disease prevention and early intervention.

However, challenges remain before clinical use of PRS becomes a reality. Currently, the vast majority of published GWAS have been conducted on the non-Hispanic white population [106]. PRS trained from European samples are known to have drastically reduced prediction accuracy in non-European populations [107]. In addition, substantially reduced predictive performance has been observed across different demographic groups even within an ancestry population [108]. Similar reduction of PRS predictive power is also observed within families (e.g., between siblings), suggesting that a substantial fraction of genetic association estimated from GWAS may be mediated by the family environments [84]. To better understand the biological mechanisms of genetic associations underlying the trait-associated loci, it will be critical to distinguish causal effects from environmental (and familial) confounding, and to explain the lack of portability of PRS between the sexes, across the social economic status spectrum, and in diverse ancestral populations before we can appropriately apply PRS to the general populations.

8. Gene Therapy

A primary objective of human genetic studies is to uncover novel genetic etiology to disease and elucidate pathomechanistic features to develop meaningful therapies for patients. Among the most-promulgated forms of novel therapies stemming from human genetic studies is gene therapy, which seeks to alter the biological properties of living cells by modifying or modulating the gene function and expression in cells [109]. Being potentially curative, gene therapy has the capacity to spare patients' years of drug intake in favor of one-time treatments with lifelong efficacy.

While gene therapy techniques can target both somatic and germline cells, ethical concerns about introducing heritable changes to humans have prevented the U.S. Food and Drug Administration (FDA) from approving any therapies targeting germline cells. Different strategies for different types of diseases have been developed in past decades: (a) inserting a functional copy of a gene to restore the biological function disrupted by a deficient copy [110]; (b) providing an interference molecular segment (i.e., small interfering RNA, suppressor gene, etc.) to inhibit the deficient gene function [111]; (c) correcting the deficient copy of a gene using genome editing techniques; and (d) adoptively transferring genetically engineered cells (e.g., hematopoietic stem cells or T cells) to restore or eliminate the dysfunctional cells [112].

Generally, drug development is divided into five steps: discovery, preclinical research, clinical research, FDA review, and post-market monitoring. This process is lengthy and expensive, taking up to 12–15 years with costs of more than USD 1 billion and increasing every year. At the same time, conventional drug development has slowed exponentially,

with the number of new drugs brought to market per billion USD spent on research and development decreasing ten-fold since 1980 and fifty-fold since 1960 [113]. Thus, robust human genetic studies and integrative multi-omics analyses have become an attractive high-throughput, hypothesis-free methodology to identify potential targets and explicate pathomechanisms to better inform drug development [114]. Moreover, these targets feed into gene therapy development, which, with further study, may present a safe and adaptable system to provide curative therapies for a variety of genetic disorders. Currently, thousands of clinical trials for gene therapy targeting different diseases are ongoing in the US, but the gene therapy technologies are still in a constant state of development and improvement.

In a poignant example of this ‘base pairs-to-bedside’ approach to drug development, until 2017 sickle cell disease (SCD), one of the most common inherited blood disorders, had seen no therapeutic innovation to meet unmet clinical needs in over 20 years. Thanks to the progress of disease association analysis and advanced genetic engineering, more-specific drugs (i.e., Oxbryta and Adakveo) have become available in the past 3 years [115–117]. Since the SCD phenotype arises from a monogenic defect affecting the β -globin gene [118], the current strategies for gene therapy treatment are relatively straightforward. The defective β -globin gene function is corrected either by providing a fully functional copy of the gene or by restoring the expression of the γ -globin gene, a transitory paralog of β -globin appearing in fetal development. The approach for SCD requires gene modification in hematopoietic stem cells from the patient followed by transplantation of the functional cells. An ongoing clinical trial (ClinicalTrials.gov numbers, NCT03282656) showed a promising outcome, whereby the patient had prompt hematopoietic reconstitution after treatment [119]. There are many other inherited diseases with FDA-approved gene therapy treatments, including β -thalassemia [120], amyotrophic lateral sclerosis [121], autosomal dominant non-syndromic hearing loss [122], hemophilia A and B [123,124], retinal dystrophy [125–129], spinal muscular atrophy [130], and cystic fibrosis [131] (Table 2). With many more gene therapy treatments still in ongoing development or clinical trials, it is reasonable to expect significant growth in gene therapy applications as the technology matures and analytical genomic science further increases successful therapeutic yield.

Table 2. Commercially Available Gene Therapies in the U.S. in Alphabetical Order (2021) [132].

Name	Manufacturer	Target Disease	Gene of Interest	FDA Approval Date
Abecma (<i>idecabtagene vicleucel</i>)	Celgene Corporation (Bristol-Myers Squibb Company)	Relapsed or refractory multiple myeloma	BCMA (B-cell maturation antigen)	March 2021 [133]
Breyanzi (<i>lisocabtagene maraleucel</i>)	Juno Therapeutics (Bristol-Myers Squibb Company)	Relapsed or refractory large B-cell lymphoma	CD137 (4-1BB TNF-receptor) and CD3-zeta	February 2021 [134]
Imlygic (<i>talimogene laherparepvec</i>)	BioVex (Subsidiary of Amgen)	Melanoma (unresectable cutaneous, subcutaneous, and nodal lesions)	GM-CSF (immune stimulatory protein)	October 2015 [135]
Kymriah (<i>tisagenlecleucel</i>)	Novartis Pharmaceuticals Corporation	Pediatric B-cell precursor acute lymphoblastic leukemia (ALL)	CD137 (4-1BB TNF-receptor) and CD3-zeta	August 2017 [136]
		Relapsed or refractory large B-cell lymphoma in adult	CD137 (4-1BB TNF-receptor) and CD3-zeta	May 2018 [136]

Table 2. Cont.

Name	Manufacturer	Target Disease	Gene of Interest	FDA Approval Date
Luxturna (voretigene neparvovec-rzyl)	Spark Therapeutics	Retinal dystrophy (biallelic RPE65 mutation- associated)	RPE65 (human retinal pigment epithelial 65 kDa protein)	December 2017 [137]
Provenge (sipuleucel-t)	Dendreon Corporation	Asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer (mCRPC)	ACP3 (prostate acid phosphatase)	April 2010 [138]
Tecartus (brexucabtagene autoleucel)	Kite Pharma	Relapsed or refractory mantle cell lymphoma (MCL) in adult	CD28 and CD3-zeta	July 2020 [139]
		Relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL) in adult	CD28 and CD3-zeta	October 2021 [139]
Yescarta (axicabtagene ciloleucel)	Kite Pharma	Relapsed or refractory large B-cell lymphoma	CD28 and CD3-zeta	October 2017 [140]
		Relapsed or refractory follicular lymphoma	CD28 and CD3-zeta	March 2021 [140]
Zolgensma (onasemnogene abeparvovec-xioi)	Novartis Gene Therapies (Formerly AveXis)	Spinal muscular atrophy (Type I)	SMN1 (human survival motor neuron 1 protein)	May 2019 [141]

Licensed gene therapies in the U.S. approved by the Office of Tissues and Advanced Therapies (OTAT) as of 26 October 2021. Name = trade name (proper name); Manufacturer = name of pharmaceutical / biotechnology company licensed; Target Disease = FDA approved indication(s) excluding disease state(s) in ongoing clinical trials; Gene of Interest = biological/therapy target (and encoded protein if applicable); FDA approval date = indication license date based on FDA approval letters.

9. Conclusions

The past decade has been the most fascinating era in the field of human genetics. We have witnessed unprecedented advances in biotechnologies for high-throughput omics, the creation of numerous global biobank cohorts with rich genotypic and phenotypic information, and the emergence of sophisticated statistical and computational methods for disease gene mapping and risk prediction. In this review, we introduced the state-of-art methods for research applications based on the study design (i.e., population, or trio-based family), genomic technology (i.e., WES, WGS, and GWAS), and the type of genetic variations under investigation (i.e., de novo, recessive, transmitted, X-linked, and digenic). We also discussed the current best practices of genomic study in human disorders—gene therapy—and summarized currently available treatments for diseases (Table 2).

As demonstrated in many studies, genetic variations alter patient responses to clinical treatments [142–144]. Although much progress has been made in identifying the genetic etiologies of many complex diseases, additional investigation is required to functionally connect most genetic variants with disease phenotypes through molecular pathomechanisms. The advent of GWAS/WES and, more recently, WGS has equipped molecular geneticists with the tools needed to decipher the genetic etiologies of rare and complex diseases. Current multi-omics studies using single-cell RNA-sequencing, ChIP-seq, and ATAC-seq have revealed more comprehensive complex biological molecules involved in the structure, function, and dynamics of a cell, tissue, or organism (reviewed in Ref. [145]). The integration of these novel technologies presents new hope in explicating the functional

impact of many disease risk variants and the genetic pathology of complex disease traits. For many patients, this represents the end of a lifelong diagnostic odyssey preventing them from receiving precision therapy, understanding their prognosis, and making important life-planning decisions.

Many in the field speculate that, as WES/WGS becomes increasingly more common and affordable, increased understanding of variant–phenotype relationships and novel integrative genomic and pharmacogenomic therapeutic approaches tailored to patient-specific genetic information may revolutionize clinical care by increasing treatment specificity [146,147]. Quantitative phenomics is a critical component of the evolving integrative genomic approach. Standardized human phenotype annotation databases [148,149] and novel phenotype clustering algorithms [150,151] are developing to enable much more comprehensive and intelligent phenomics analysis. Transitioning to high quality, electronic, and increasingly standardized phenomics information can improve the phenotypic characterization of various heterogeneous disorders and identify associations between certain genetic variants and their respective clinical outcomes or presentation. This thereby provides better prognostication and clinical management, particularly of disorders with highly varied and poorly differentiated intra-disorder phenotypes [152,153]. Incorporating patient genetic information into clinician-friendly data platforms (i.e., electronic medical records) will maximize drug efficacy and minimize adverse effects, enriching precision medicine in practice [154]. The interface between genomic information and electronic health records coupled with increasingly improved methods can facilitate more precise discovery of genetic variants to guide more accurate therapeutic decisions in the future.

Author Contributions: Conceptualization, S.C.J. and Q.L.; writing—original draft preparation, Y.-C.W., Y.W., J.C., G.A., S.Z., M.K., K.Y., Q.L. and S.C.J.; writing—review and editing, Y.-C.W., Y.W., J.C., G.A., S.Z., M.K., K.Y., P.-Y.F., M.W., X.Y., K.Y.M., J.O., H.S., J.S., K.T.K., Q.L. and S.C.J.; supervision, Q.L., S.C.J. project administration, Y.-C.W., Y.W., J.C., G.A., S.Z., M.K., K.Y., Q.L. and S.C.J.; funding acquisition, K.T.K., Q.L. and S.C.J. All authors have read and agreed to the published version of the manuscript.

Funding: S.C.J. is supported by NIH/National Heart Lung and Blood Institute (NHLBI) Pathway to Independence award R00HL143036-02, the Hydrocephalus Association Innovator Award, the Clinical & Translational Research Funding Program award (CTSA1405), and the Children’s Discovery Institute Faculty Scholar award (CDI-FR-2021-926). K.T.K. is supported by the NIH (NRCDP K12 228168, 1R01NS109358, and R01 NS111029-01A1); the Hydrocephalus Association; the Rudi Schulte Research Institute; and the Simons Foundation. G.A. is supported by the Gruber Science Fellowship. Q.L. and Y.W. gratefully acknowledge support from the Center for Demography of Health and Aging at the University of Wisconsin-Madison, funded by NIA Center Grant P30 AG017266. This project was funded, in whole or in part, by the Foundation for Barnes-Jewish Hospital and their generous donors and by the NIH/National Center for Advancing Translational Sciences grant UL1TR002345, as well as the Children’s Discovery Institute of Washington University and St. Louis Children’s Hospital.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: Not applicable.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Bycroft, C.; Freeman, C.; Petkova, D.; Band, G.; Elliott, L.T.; Sharp, K.; Motyer, A.; Vukcevic, D.; Delaneau, O.; O’Connell, J.; et al. The UK Biobank resource with deep phenotyping and genomic data. *Nature* **2018**, *562*, 203–209. [[CrossRef](#)] [[PubMed](#)]
2. Consortium ITP-CAoWG. Pan-cancer analysis of whole genomes. *Nature* **2020**, *578*, 82–93. [[CrossRef](#)] [[PubMed](#)]
3. The 1000 Genomes Project Consortium. A global reference for human genetic variation. *Nature* **2015**, *526*, 68–74. [[CrossRef](#)] [[PubMed](#)]
4. Kaplanis, J.; Samocha, K.E.; Wiel, L.; Zhang, Z.; Arvai, K.J.; Eberhardt, R.Y.; Gallone, G.; Lelieveld, S.H.; Martin, H.C.; McRae, J.F.; et al. Evidence for 28 genetic disorders discovered by combining healthcare and research data. *Nature* **2020**, *586*, 757–762. [[CrossRef](#)] [[PubMed](#)]

5. Klein, R.J.; Zeiss, C.; Chew, E.Y.; Tsai, J.-Y.; Sackler, R.S.; Haynes, C.; Henning, A.K.; SanGiovanni, J.P.; Mane, S.M.; Mayne, S.T.; et al. Complement factor H polymorphism in age-related macular degeneration. *Science* **2005**, *308*, 385–389. [[CrossRef](#)]
6. Samani, N.J.; Erdmann, J.; Hall, A.S.; Hengstenberg, C.; Mangino, M.; Mayer, B.; Dixon, R.J.; Meitinger, T.; Braund, P.; Wichmann, H.-E.; et al. Genomewide association analysis of coronary artery disease. *N. Engl. J. Med.* **2007**, *357*, 443–453. [[CrossRef](#)]
7. Frayling, T.M.; Timpson, N.J.; Weedon, M.N.; Zeggini, E.; Freathy, R.M.; Lindgren, C.M.; Perry, J.R.B.; Elliott, K.S.; Lango, H.; Rayner, N.W.; et al. A common variant in the FTO gene is associated with body mass index and predisposes to childhood and adult obesity. *Science* **2007**, *316*, 889–894. [[CrossRef](#)]
8. Herbert, A.; Gerry, N.P.; McQueen, M.B.; Heid, I.M.; Pfeufer, A.; Illig, T.; Wichmann, H.-E.; Meitinger, T.; Hunter, D.; Hu, F.B.; et al. A common genetic variant is associated with adult and childhood obesity. *Science* **2006**, *312*, 279–283. [[CrossRef](#)]
9. Saxena, R.; Voight, B.F.; Lyssenko, V.; Burt, N.P.; de Bakker, P.I.W.; Chen, H.; Roix, J.J.; Kathiresan, S.; Hirschhorn, J.N.; Daly, M.J.; et al. Genome-wide association analysis identifies loci for type 2 diabetes and triglyceride levels. *Science* **2007**, *316*, 1331–1336. [[CrossRef](#)]
10. Stefansson, H.; Ophoff, R.A.; Steinberg, S.; Andreassen, O.A.; Cichon, S.; Rujescu, D.; Werge, T.; Pietilainen, O.P.; Mors, O.; Mortensen, P.B.; et al. Common variants conferring risk of schizophrenia. *Nature* **2009**, *460*, 744–747. [[CrossRef](#)]
11. Buniello, A.; MacArthur, J.A.L.; Cerezo, M.; Harris, L.W.; Hayhurst, J.; Malangone, C.; McMahon, A.; Morales, J.; Mountjoy, E.; Sollis, E.; et al. The NHGRI-EBI GWAS Catalog of published genome-wide association studies, targeted arrays and summary statistics 2019. *Nucleic Acids Res.* **2019**, *47*, D1005–D1012. [[CrossRef](#)]
12. Manolio, T.A.; Collins, F.S.; Cox, N.J.; Goldstein, D.B.; Hindorf, L.A.; Hunter, D.J.; McCarthy, M.I.; Ramos, E.M.; Cardon, L.R.; Chakravarti, A.; et al. Finding the missing heritability of complex diseases. *Nature* **2009**, *461*, 747–753. [[CrossRef](#)] [[PubMed](#)]
13. Guo, M.H.; Dauber, A.; Lippincott, M.; Chan, Y.-M.; Salem, R.; Hirschhorn, J.N. Determinants of Power in Gene-Based Burden Testing for Monogenic Disorders. *Am. J. Hum. Genet.* **2016**, *99*, 527–539. [[CrossRef](#)] [[PubMed](#)]
14. Li, B.; Leal, S.M. Methods for detecting associations with rare variants for common diseases: Application to analysis of sequence data. *Am. J. Hum. Genet.* **2008**, *83*, 311–321. [[CrossRef](#)] [[PubMed](#)]
15. Price, A.L.; Kryukov, G.; de Bakker, P.I.; Purcell, S.M.; Staples, J.; Wei, L.-J.; Sunyaev, S.R. Pooled association tests for rare variants in exon-resequencing studies. *Am. J. Hum. Genet.* **2010**, *86*, 832–838. [[CrossRef](#)] [[PubMed](#)]
16. Wu, M.C.; Lee, S.; Cai, T.; Li, Y.; Boehnke, M.; Lin, X. Rare-variant association testing for sequencing data with the sequence kernel association test. *Am. J. Hum. Genet.* **2011**, *89*, 82–93. [[CrossRef](#)] [[PubMed](#)]
17. Morgenthaler, S.; Thilly, W.G. A strategy to discover genes that carry multi-allelic or mono-allelic risk for common diseases: A cohort allelic sums test (CAST). *Mutat. Res.* **2007**, *615*, 28–56. [[CrossRef](#)] [[PubMed](#)]
18. Wang, T.; Elston, R.C. Improved power by use of a weighted score test for linkage disequilibrium mapping. *Am. J. Hum. Genet.* **2007**, *80*, 353–360. [[CrossRef](#)]
19. Liu, D.J.; Leal, S.M. A novel adaptive method for the analysis of next-generation sequencing data to detect complex trait associations with rare variants due to gene main effects and interactions. *PLoS Genet.* **2010**, *6*, e1001156. [[CrossRef](#)]
20. Liu, J.Z.; Mcrae, A.F.; Nyholt, D.R.; Medland, S.E.; Wray, N.R.; Brown, K.M.; Hayward, N.K.; Montgomery, G.; Visscher, P.; Martin, N.; et al. A versatile gene-based test for genome-wide association studies. *Am. J. Hum. Genet.* **2010**, *87*, 139–145. [[CrossRef](#)]
21. Li, M.-X.; Gui, H.-S.; Kwan, J.S.; Sham, P.C. GATES: A rapid and powerful gene-based association test using extended Simes procedure. *Am. J. Hum. Genet.* **2011**, *88*, 283–293. [[CrossRef](#)] [[PubMed](#)]
22. Lee, S.; Won, S.; Kim, Y.J.; Kim, Y.; Consortium, T.D.-G.; Kim, B.J.; Park, T. Rare variant association test with multiple phenotypes. *Genet. Epidemiol.* **2017**, *41*, 198–209. [[CrossRef](#)] [[PubMed](#)]
23. Luo, L.; Shen, J.; Zhang, H.; Chhibber, A.; Mehrotra, D.V.; Tang, Z.-Z. Multi-trait analysis of rare-variant association summary statistics using MTAR. *Nat. Commun.* **2020**, *11*, 2850. [[CrossRef](#)] [[PubMed](#)]
24. Lee, S.; Abecasis, G.R.; Boehnke, M.; Lin, X. Rare-variant association analysis: Study designs and statistical tests. *Am. J. Hum. Genet.* **2014**, *95*, 5–23. [[CrossRef](#)]
25. O’Roak, B.J.; Vives, L.; Fu, W.; Egertson, J.D.; Stanaway, I.B.; Phelps, I.G.; Carvill, G.; Kumar, A.; Lee, C.; Ankenman, K.; et al. Multiplex targeted sequencing identifies recurrently mutated genes in autism spectrum disorders. *Science* **2012**, *338*, 1619–1622. [[CrossRef](#)]
26. Ware, J.; Samocha, K.; Homsy, J.; Daly, M.J. Interpreting de novo Variation in Human Disease Using denovolyzeR. *Curr. Protoc. Hum. Genet.* **2015**, *87*, 7.25.1–7.25.15. [[CrossRef](#)]
27. Jin, S.C.; Homsy, J.; Zaidi, S.; Lu, Q.; Morton, S.; DePalma, S.R.; Zeng, X.; Qi, H.; Chang, W.; Sierant, M.C.; et al. Contribution of rare inherited and de novo variants in 2871 congenital heart disease probands. *Nat. Genet.* **2017**, *49*, 1593–1601. [[CrossRef](#)]
28. Akawi, N.; McRae, J.; Ansari, M.; Balasubramanian, M.; Blyth, M.; Brady, A.F.; Clayton, S.; Cole, T.; Deshpande, C.; Fitzgerald, T.W.; et al. Discovery of four recessive developmental disorders using probabilistic genotype and phenotype matching among 4125 families. *Nat. Genet.* **2015**, *47*, 1363–1369. [[CrossRef](#)]
29. Martin, H.C.; Jones, W.D.; McIntyre, R.; Sanchez-Andrade, G.; Sanderson, M.; Stephenson, J.D.; Jones, C.P.; Handsaker, J.; Gallone, G.; Bruntraeger, M.; et al. Quantifying the contribution of recessive coding variation to developmental disorders. *Science* **2018**, *362*, 1161–1164. [[CrossRef](#)]

30. He, X.; Sanders, S.; Liu, L.; De Rubeis, S.; Lim, T.T.; Sutcliffe, J.S.; Schellenberg, G.D.; Gibbs, R.A.; Daly, M.J.; Buxbaum, J.; et al. Integrated model of de novo and inherited genetic variants yields greater power to identify risk genes. *PLoS Genet.* **2013**, *9*, e1003671. [[CrossRef](#)]
31. Nguyen, H.T.; Bryois, J.; Kim, A.; Dobbyn, A.; Huckins, L.M.; Munoz-Manchado, A.B.; Ruderfer, D.M.; Genovese, G.; Fromer, M.; Xu, X.; et al. Integrated Bayesian analysis of rare exonic variants to identify risk genes for schizophrenia and neurodevelopmental disorders. *Genome Med.* **2017**, *9*, 114. [[CrossRef](#)] [[PubMed](#)]
32. Liu, Y.; Liang, Y.; Cicek, A.E.; Li, Z.; Li, J.; Muhle, R.A.; Krenzer, M.; Mei, Y.; Wang, Y.; Knoblauch, N.; et al. A Statistical Framework for Mapping Risk Genes from De Novo Mutations in Whole-Genome-Sequencing Studies. *Am. J. Hum. Genet.* **2018**, *102*, 1031–1047. [[CrossRef](#)] [[PubMed](#)]
33. Li, M.; Zeng, X.; Jin, C.; Jin, S.C.; Dong, W.; Brueckner, M.; Lifton, R.; Lu, Q.; Zhao, H. Integrative modeling of transmitted and de novo variants identifies novel risk genes for congenital heart disease. *Quant. Biol.* **2021**, *9*, 216–227. [[CrossRef](#)]
34. Nguyen, T.-H.; Dobbyn, A.; Brown, R.C.; Riley, B.P.; Buxbaum, J.; Pinto, D.; Purcell, S.M.; Sullivan, P.F.; He, X.; Stahl, E.A. mTADA is a framework for identifying risk genes from de novo mutations in multiple traits. *Nat. Commun.* **2020**, *11*, 2929. [[CrossRef](#)]
35. Wang, J.; Yu, R.; Shete, S. X-chromosome genetic association test accounting for X-inactivation, skewed X-inactivation, and escape from X-inactivation. *Genet. Epidemiol.* **2014**, *38*, 483–493. [[CrossRef](#)]
36. Clayton, D. Testing for association on the X chromosome. *Biostatistics* **2008**, *9*, 593–600. [[CrossRef](#)]
37. Jin, H.; Park, T.; Won, S. Efficient Statistical Method for Association Analysis of X-Linked Variants. *Hum. Hered.* **2016**, *82*, 50–63. [[CrossRef](#)]
38. Martin, H.C.; Gardner, E.J.; Samocha, K.E.; Kaplanis, J.; Akawi, N.; Sifrim, A.; Eberhardt, R.Y.; Tavares, A.L.T.; Neville, M.D.C.; Niemi, M.E.K.; et al. The contribution of X-linked coding variation to severe developmental disorders. *Nat. Commun.* **2021**, *12*, 627. [[CrossRef](#)]
39. March, R.E. Gene mapping by linkage and association analysis. *Mol. Biotechnol.* **1999**, *13*, 113–122. [[CrossRef](#)]
40. Tabor, H.K.; Risch, N.J.; Myers, R.M. Candidate-gene approaches for studying complex genetic traits: Practical considerations. *Nat. Rev. Genet.* **2002**, *3*, 391–397. [[CrossRef](#)]
41. Kerner, G.; Bouaziz, M.; Cobat, A.; Bigio, B.; Timberlake, A.T.; Bustamante, J.; Lifton, R.P.; Casanova, J.-L.; Abel, L. A genome-wide case-only test for the detection of digenic inheritance in human exomes. *Proc. Natl. Acad. Sci. USA* **2020**, *117*, 19367–19375. [[CrossRef](#)] [[PubMed](#)]
42. Chen, X.; Ishwaran, H. Random forests for genomic data analysis. *Genomics* **2012**, *99*, 323–329. [[CrossRef](#)] [[PubMed](#)]
43. Thomas, D.C.; Yang, Z.; Yang, F. Two-phase and family-based designs for next-generation sequencing studies. *Front. Genet.* **2013**, *4*, 276. [[CrossRef](#)] [[PubMed](#)]
44. Sanders, S.J.; Murtha, M.T.; Gupta, A.R.; Murdoch, J.D.; Raubeson, M.J.; Willsey, A.J.; Ercan-Sencicek, A.G.; DiLullo, N.M.; Parikshak, N.N.; Stein, J.L.; et al. De novo mutations revealed by whole-exome sequencing are strongly associated with autism. *Nature* **2012**, *485*, 237–241. [[CrossRef](#)] [[PubMed](#)]
45. Zaidi, S.; Choi, M.; Wakimoto, H.; Ma, L.; Jiang, J.; Overton, J.D.; Romano-Adesman, A.; Bjornson, R.D.; Breitbart, R.E.; Brown, K.K.; et al. De novo mutations in histone-modifying genes in congenital heart disease. *Nature* **2013**, *498*, 220–223. [[CrossRef](#)]
46. Feng, T.; Zhang, S.; Sha, Q. Two-stage association tests for genome-wide association studies based on family data with arbitrary family structure. *Eur. J. Hum. Genet.* **2007**, *15*, 1169–1175. [[CrossRef](#)] [[PubMed](#)]
47. Lange, C.; DeMeo, D.; Silverman, E.K.; Weiss, S.T.; Laird, N.M. Using the noninformative families in family-based association tests: A powerful new testing strategy. *Am. J. Hum. Genet.* **2003**, *73*, 801–811. [[CrossRef](#)]
48. Murphy, A.; Weiss, S.T.; Lange, C. Screening and replication using the same data set: Testing strategies for family-based studies in which all probands are affected. *PLoS Genet.* **2008**, *4*, e1000197. [[CrossRef](#)]
49. Van Steen, K.; McQueen, M.B.; Herbert, A.; Raby, B.; Lyon, H.; DeMeo, D.L.; Murphy, A.; Su, J.; Datta, S.; Rosenow, C.; et al. Genomic screening and replication using the same data set in family-based association testing. *Nat. Genet.* **2005**, *37*, 683–691. [[CrossRef](#)]
50. Homsy, J.; Zaidi, S.; Shen, Y.; Ware, J.S.; Samocha, K.E.; Karczewski, K.J.; DePalma, S.R.; McKean, D.; Wakimoto, H.; Gorham, J.; et al. De novo mutations in congenital heart disease with neurodevelopmental and other congenital anomalies. *Science* **2015**, *350*, 1262–1266. [[CrossRef](#)]
51. Sifrim, A.; Hitz, M.-P.; Wilsdon, A.; Breckpot, J.; Al Turki, S.H.; Thienpont, B.; McRae, J.; Fitzgerald, T.W.; Singh, T.; Swaminathan, G.J.; et al. Distinct genetic architectures for syndromic and nonsyndromic congenital heart defects identified by exome sequencing. *Nat. Genet.* **2016**, *48*, 1060–1065. [[CrossRef](#)] [[PubMed](#)]
52. Conrad, D.F.; Keebler, J.E.; De Pristo, M.A.; Lindsay, S.J.; Zhang, Y.; Cassals, F.; Idaghdour, Y.; Hartl, C.L.; Torroja, C.; Garimella, K.V.; et al. Variation in genome-wide mutation rates within and between human families. *Nat. Genet.* **2011**, *43*, 712–714. [[CrossRef](#)] [[PubMed](#)]
53. Lynch, M. Rate, molecular spectrum, and consequences of human mutation. *Proc. Natl. Acad. Sci. USA* **2010**, *107*, 961–968. [[CrossRef](#)] [[PubMed](#)]
54. Samocha, K.; Robinson, E.; Sanders, S.; Stevens, C.; Sabo, A.; McGrath, L.; Kosmicki, J.A.; Rehnström, K.; Mallick, S.; Kirby, A.; et al. A framework for the interpretation of de novo mutation in human disease. *Nat. Genet.* **2014**, *46*, 944–950. [[CrossRef](#)]

55. Karczewski, K.J.; Francioli, L.C.; Tiao, G.; Cummings, B.B.; Alfoldi, J.; Wang, Q.; Collins, R.L.; Laricchia, K.M.; Ganna, A.; Birnbaum, D.P.; et al. The mutational constraint spectrum quantified from variation in 141,456 humans. *Nature* **2020**, *581*, 434–443. [[CrossRef](#)]
56. An, J.-Y.; Lin, K.; Zhu, L.; Werling, D.M.; Dong, S.; Brand, H.; Wang, H.Z.; Zhao, X.; Schwartz, G.B.; Collins, R.L.; et al. Genome-wide de novo risk score implicates promoter variation in autism spectrum disorder. *Science* **2018**, *362*, eaat6576. [[CrossRef](#)]
57. Sayres, M.A.W. Genetic Diversity on the Sex Chromosomes. *Genome Biol. Evol.* **2018**, *10*, 1064–1078. [[CrossRef](#)]
58. Peeters, S.B.; Cotton, A.M.; Brown, C.J. Variable escape from X-chromosome inactivation: Identifying factors that tip the scales towards expression. *Bioessays* **2014**, *36*, 746–756. [[CrossRef](#)]
59. Heard, E.; Chaumeil, J.; Masui, O.; Okamoto, I. Mammalian X-chromosome inactivation: An epigenetics paradigm. *Cold Spring Harb. Symp. Quant. Biol.* **2004**, *69*, 89–102. [[CrossRef](#)]
60. Wong, C.; Caspi, A.; Williams, B.; Houts, R.; Craig, I.W.; Mill, J. A longitudinal twin study of skewed X chromosome-inactivation. *PLoS ONE* **2011**, *6*, e17873. [[CrossRef](#)]
61. Wang, J.; Talluri, R.; Shete, S. Selection of X-chromosome Inactivation Model. *Cancer Inform.* **2017**, *16*, 1176935117747272. [[CrossRef](#)] [[PubMed](#)]
62. Busque, L.; Paquette, Y.; Provost, S.; Roy, D.-C.; Levine, R.L.; Mollica, L.; Gilliland, D.G. Skewing of X-inactivation ratios in blood cells of aging women is confirmed by independent methodologies. *Blood* **2009**, *113*, 3472–3474. [[CrossRef](#)] [[PubMed](#)]
63. Knudsen, G.; Pedersen, J.; Klingenberg, O.; Lygren, I.; Ørstavik, K. Increased skewing of X chromosome inactivation with age in both blood and buccal cells. *Cytogenet. Genome Res.* **2007**, *116*, 24–28. [[CrossRef](#)] [[PubMed](#)]
64. Schaffer, A.A. Digenic inheritance in medical genetics. *J. Med. Genet.* **2013**, *50*, 641–652. [[CrossRef](#)] [[PubMed](#)]
65. Pasche, B.; Yi, N. Candidate gene association studies: Successes and failures. *Curr. Opin. Genet. Dev.* **2010**, *20*, 257–261. [[CrossRef](#)] [[PubMed](#)]
66. Yang, Q.; Khoury, M.J.; Sun, F.; Flanders, W.D. Case-only design to measure gene-gene interaction. *Epidemiology* **1999**, *10*, 167–170. [[CrossRef](#)] [[PubMed](#)]
67. Begg, C.B.; Zhang, Z.F. Statistical analysis of molecular epidemiology studies employing case-series. *Cancer Epidemiol. Biomark. Prev.* **1994**, *3*, 173–175.
68. Piegorsch, W.W.; Weinberg, C.R.; Taylor, J.A. Non-hierarchical logistic models and case-only designs for assessing susceptibility in population-based case-control studies. *Stat. Med.* **1994**, *13*, 153–162. [[CrossRef](#)]
69. McKinney, B.A.; Reif, D.; Ritchie, M.D.; Moore, J.H. Machine learning for detecting gene-gene interactions: A review. *Appl. Bioinform.* **2006**, *5*, 77–88. [[CrossRef](#)]
70. Byrjalsen, A.; Hansen, T.V.O.; Stoltze, U.K.; Mehrjouy, M.M.; Barnkob, N.M.; Hjalgrim, L.L.; Mathiasen, R.; Lautrup, C.K.; Gregersen, P.A.; Hasle, H.; et al. Nationwide germline whole genome sequencing of 198 consecutive pediatric cancer patients reveals a high incidence of cancer prone syndromes. *PLoS Genet.* **2020**, *16*, e1009231. [[CrossRef](#)]
71. Costantini, A.; Valta, H.; Suomi, A.-M.; Mäkitie, O.; Taylan, F. Oligogenic Inheritance of Monoallelic TRIP11, FKBP10, NEK1, TBX5, and NBAS Variants Leading to a Phenotype Similar to Odontochondrodysplasia. *Front. Genet.* **2021**, *12*, 680838. [[CrossRef](#)] [[PubMed](#)]
72. Dallali, H.; Kheriji, N.; Kammoun, W.; Mrad, M.; Soltani, M.; Trabelsi, H.; Hamdi, W.; Bahlous, A.; Ben Ahmed, M.; Mahjoub, F.; et al. Multiallelic Rare Variants in BBS Genes Support an Oligogenic Ciliopathy in a Non-obese Juvenile-Onset Syndromic Diabetic Patient: A Case Report. *Front. Genet.* **2021**, *12*, 664963. [[CrossRef](#)] [[PubMed](#)]
73. Zhao, T.; Ma, Y.; Zhang, Z.; Xian, J.; Geng, X.; Wang, F.; Huang, J.; Yang, Z.; Luo, Y.; Lin, Y. Young and early-onset dilated cardiomyopathy with malignant ventricular arrhythmia and sudden cardiac death induced by the heterozygous LDB3, MYH6, and SYNE1 missense mutations. *Ann. Noninvasive Electrocardiol.* **2021**, *26*, e12840. [[CrossRef](#)] [[PubMed](#)]
74. Libbrecht, M.; Noble, W.S. Machine learning applications in genetics and genomics. *Nat. Rev. Genet.* **2015**, *16*, 321–332. [[CrossRef](#)] [[PubMed](#)]
75. Nicholls, H.L.; John, C.R.; Watson, D.; Munroe, P.B.; Barnes, M.R.; Cabrera, C.P. Reaching the End-Game for GWAS: Machine Learning Approaches for the Prioritization of Complex Disease Loci. *Front. Genet.* **2020**, *11*, 350. [[CrossRef](#)] [[PubMed](#)]
76. Li, Y.; Yagi, H.; Onuoha, E.O.; Damerla, R.R.; Francis, R.; Furutani, Y.; Tariq, M.; King, S.M.; Hendricks, G.; Cui, C.; et al. DNAH6 and Its Interactions with PCD Genes in Heterotaxy and Primary Ciliary Dyskinesia. *PLoS Genet.* **2016**, *12*, e1005821. [[CrossRef](#)]
77. Gifford, C.A.; Ranade, S.S.; Samarakoon, R.; Salunga, H.T.; de Soysa, T.Y.; Huang, Y.; Zhou, P.; Elfenbein, A.; Wyman, S.K.; Bui, Y.K.; et al. Oligogenic inheritance of a human heart disease involving a genetic modifier. *Science* **2019**, *364*, 865–870. [[CrossRef](#)]
78. Das, S.; Forer, L.; Schönherr, S.; Sidore, C.; Locke, A.E.; Kwong, A.; Vrieze, S.I.; Chew, E.Y.; Levy, S.; McGue, M.; et al. Next-generation genotype imputation service and methods. *Nat. Genet.* **2016**, *48*, 1284–1287. [[CrossRef](#)]
79. Visscher, P.M.; Wray, N.R.; Zhang, Q.; Sklar, P.; McCarthy, M.I.; Brown, M.A.; Yang, J. 10 years of GWAS discovery: Biology, function, and translation. *Am. J. Hum. Genet.* **2017**, *101*, 5–22. [[CrossRef](#)]
80. Willer, C.; Li, Y.; Abecasis, G.R. METAL: Fast and efficient meta-analysis of genomewide association scans. *Bioinformatics* **2010**, *26*, 2190–2191. [[CrossRef](#)]
81. Uffelmann, E.; Huang, Q.Q.; Munung, N.S.; de Vries, J.; Okada, Y.; Martin, A.R.; Martin, H.C.; Lappalainen, T.; Posthuma, D. Genome-wide association studies. *Nat. Rev. Methods Primers* **2021**, *1*, 59. [[CrossRef](#)]
82. Chatterjee, N.; Shi, J.; García-Closas, M. Developing and evaluating polygenic risk prediction models for stratified disease prevention. *Nat. Rev. Genet.* **2016**, *17*, 392–406. [[CrossRef](#)]

83. Kong, A.; Thorleifsson, G.; Frigge, M.L.; Vilhjalmsón, B.J.; Young, A.I.; Thorgeirsson, T.E.; Benonisdóttir, S.; Oddsson, A.; Halldorsson, B.V.; Masson, G.; et al. The nature of nurture: Effects of parental genotypes. *Science* **2018**, *359*, 424–428. [[CrossRef](#)] [[PubMed](#)]
84. Young, A.I.; Benonisdóttir, S.; Przeworski, M.; Kong, A. Deconstructing the sources of genotype-phenotype associations in humans. *Science* **2019**, *365*, 1396–1400. [[CrossRef](#)]
85. Howe, L.J.; Nivard, M.G.; Morris, T.T.; Hansen, A.F.; Rasheed, H.; Cho, Y.; Chittoor, G.; Lind, P.A.; Palviainen, T.; van der Zee, M.D.; et al. Within-sibship GWAS improve estimates of direct genetic effects. *bioRxiv* **2021**. [[CrossRef](#)]
86. Wu, Y.; Zhong, X.; Lin, Y.; Zhao, Z.; Chen, J.; Zheng, B.; Li, J.J.; Fletcher, J.M.; Lu, Q. Estimating genetic nurture with summary statistics of multigenerational genome-wide association studies. *Proc. Natl. Acad. Sci. USA* **2021**, *118*, e2023184118. [[CrossRef](#)]
87. Cooper, D.N.; Krawczak, M.; Polychronakos, C.; Tyler-Smith, C.; Kehrer-Sawatzki, H. Where genotype is not predictive of phenotype: Towards an understanding of the molecular basis of reduced penetrance in human inherited disease. *Hum. Genet.* **2013**, *132*, 1077–1130. [[CrossRef](#)]
88. Wei, W.; Hemani, G.; Haley, C. Detecting epistasis in human complex traits. *Nat. Rev. Genet.* **2014**, *15*, 722–733. [[CrossRef](#)]
89. Sinnott-Armstrong, N.; Naqvi, S.; Rivas, M.; Pritchard, J.K. GWAS of three molecular traits highlights core genes and pathways alongside a highly polygenic background. *eLife* **2021**, *10*, e58615. [[CrossRef](#)]
90. Wainschtein, P.; Jain, D.; Zheng, Z.; TOPMed Anthropometry Working Group; NHLBI Trans-Omics for Precision Medicine (TOPMed) Consortium; Cupples, L.A.; Shadyab, A.H.; McKnight, B.; Shoemaker, B.M.; Mitchell, B.D.; et al. Recovery of trait heritability from whole genome sequence data. *bioRxiv* **2021**. [[CrossRef](#)]
91. Crowley, J.J.; Szatkiewicz, J.; Kähler, A.K.; Giusti-Rodríguez, P.; Ancalade, N.; Booker, J.K.; Carr, J.L.; Crawford, G.E.; Losh, M.; Stockmeier, C.A.; et al. Common-variant associations with fragile X syndrome. *Mol. Psychiatry* **2019**, *24*, 338–344. [[CrossRef](#)] [[PubMed](#)]
92. Claussnitzer, M.; Cho, J.H.; Collins, R.; Cox, N.J.; Dermitzakis, E.T.; Hurles, M.E.; Kathiresan, S.; Kenny, E.E.; Lindgren, C.M.; MacArthur, D.G.; et al. A brief history of human disease genetics. *Nature* **2020**, *577*, 179–189. [[CrossRef](#)] [[PubMed](#)]
93. Cordell, H.J.; Bentham, J.; Topf, A.; Zelenika, D.; Heath, S.; Mamasoula, C.; Cosgrove, C.; Blue, G.M.; Granados-Riveron, J.T.; Setchfield, K.; et al. Genome-wide association study of multiple congenital heart disease phenotypes identifies a susceptibility locus for atrial septal defect at chromosome 4p16. *Nat. Genet.* **2013**, *45*, 822. [[CrossRef](#)] [[PubMed](#)]
94. Agopian, A.J.; Goldmuntz, E.; Hakonarson, H.; Sewda, A.; Taylor, D.; Mitchell, L.E.; Pediatric Cardiac Genomics Consortium. Genome-wide association studies and meta-analyses for congenital heart defects. *Circ. Cardiovasc. Genet.* **2017**, *10*, e001449. [[CrossRef](#)] [[PubMed](#)]
95. Weiner, D.J.; iPSYCH-Broad Autism Group; Wigdor, E.M.; Ripke, S.; Walters, R.K.; Kosmicki, J.A.; Grove, J.; Samocha, K.E.; Goldstein, J.I.; Okbay, A.; et al. Polygenic transmission disequilibrium confirms that common and rare variation act additively to create risk for autism spectrum disorders. *Nat. Genet.* **2017**, *49*, 978–985. [[CrossRef](#)] [[PubMed](#)]
96. Grove, J.; Ripke, S.; Als, T.D.; Mattheisen, M.; Walters, R.K.; Won, H.; Pallesen, J.; Agerbo, E.; Andreassen, O.A.; Anney, R.; et al. Identification of common genetic risk variants for autism spectrum disorder. *Nat. Genet.* **2019**, *51*, 431–444. [[CrossRef](#)]
97. Satterstrom, F.K.; Kosmicki, J.A.; Wang, J.; Breen, M.S.; De Rubeis, S.; An, J.-Y.; Peng, M.; Collins, R.; Grove, J.; Klei, L.; et al. Large-scale exome sequencing study implicates both developmental and functional changes in the neurobiology of autism. *Cell* **2020**, *180*, 568–584. [[CrossRef](#)]
98. Timberlake, A.T.; Choi, J.; Zaidi, S.; Lu, Q.; Nelson-Williams, C.; Brooks, E.D.; Bilguvar, K.; Tikhonova, I.; Mane, S.; Yang, J.F.; et al. Two locus inheritance of non-syndromic midline craniosynostosis via rare SMAD6 and common BMP2 alleles. *eLife* **2016**, *5*, e20125. [[CrossRef](#)]
99. Huang, K.; Wu, Y.; Shin, J.; Zheng, Y.; Siahpirani, A.F.; Lin, Y.; Ni, Z.; Chen, J.; You, J.; Keles, S.; et al. Transcriptome-wide transmission disequilibrium analysis identifies novel risk genes for autism spectrum disorder. *PLoS Genet.* **2021**, *17*, e1009309. [[CrossRef](#)]
100. Halldorsson, B.V.; Eggertsson, H.P.; Moore, K.H.S.; Hauswedell, H.; Eiriksson, O.; Ulfarsson, M.O.; Palsson, G.; Hardarson, M.T.; Oddsson, A.; Jensson, B.O.; et al. The sequences of 150,119 genomes in the UK biobank. *bioRxiv* **2021**. [[CrossRef](#)]
101. Hu, Y.; Lu, Q.; Powles, R.; Yao, X.; Yang, C.; Fang, F.; Xu, X.; Zhao, H. Leveraging functional annotations in genetic risk prediction for human complex diseases. *PLoS Comput. Biol.* **2017**, *13*, e1005589. [[CrossRef](#)] [[PubMed](#)]
102. Ruan, Y.; Anne Feng, Y.-C.; Chen, C.-Y.; Lam, M.; Sawa, A.; Martin, A.R.; Qin, S.; Huang, H.; Ge, T. Improving polygenic prediction in ancestrally diverse populations. *medRxiv* **2021**. [[CrossRef](#)]
103. Privé, F.; Arbel, J.; Vilhjalmsón, B.J. LDpred2: Better, faster, stronger. *Bioinformatics* **2020**, *36*, 5424–5431. [[CrossRef](#)] [[PubMed](#)]
104. Zhao, Z.; Yi, Y.; Song, J.; Wu, Y.; Zhong, X.; Lin, Y.; Hohman, T.J.; Fletcher, J.; Lu, Q. PUMAS: Fine-tuning polygenic risk scores with GWAS summary statistics. *Genome Biol.* **2021**, *22*, 257. [[CrossRef](#)]
105. Khera, A.V.; Chaffin, M.; Aragam, K.G.; Haas, M.E.; Roselli, C.; Choi, S.H.; Natarajan, P.; Lander, E.S.; Lubitz, S.A.; Ellinor, P.T.; et al. Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations. *Nat. Genet.* **2018**, *50*, 1219–1224. [[CrossRef](#)]
106. Mills, M.C.; Rahal, C. The GWAS diversity monitor tracks diversity by disease in real time. *Nat. Genet.* **2020**, *52*, 242–243. [[CrossRef](#)]
107. Martin, A.R.; Kanai, M.; Kamatani, Y.; Okada, Y.; Neale, B.M.; Daly, M.J. Clinical use of current polygenic risk scores may exacerbate health disparities. *Nat. Genet.* **2019**, *51*, 584–591. [[CrossRef](#)]

108. Mostafavi, H.; Harpak, A.; Agarwal, I.; Conley, D.; Pritchard, J.K.; Przeworski, M. Variable prediction accuracy of polygenic scores within an ancestry group. *eLife* **2020**, *9*, e48376. [[CrossRef](#)]
109. Friedmann, T. A brief history of gene therapy. *Nat. Genet.* **1992**, *2*, 93–98. [[CrossRef](#)]
110. Rogers, S.; Lowenthal, A.; Terheggen, H.G.; Columbo, J.P. Induction of arginase activity with the Shope papilloma virus in tissue culture cells from an argininemic patient. *J. Exp. Med.* **1973**, *137*, 1091–1096. [[CrossRef](#)]
111. Tabernero, J.; Shapiro, G.I.; Lorusso, P.M.; Cervantes, A.; Schwartz, G.K.; Weiss, G.J.; Paz-Ares, L.; Cho, D.C.; Infante, J.R.; Alsina, M.; et al. First-in-humans trial of an RNA interference therapeutic targeting VEGF and KSP in cancer patients with liver involvement. *Cancer Discov.* **2013**, *3*, 406–417. [[CrossRef](#)] [[PubMed](#)]
112. Li, H.; Yang, Y.; Hong, W.; Huang, M.; Wu, M.; Zhao, X. Applications of genome editing technology in the targeted therapy of human diseases: Mechanisms, advances and prospects. *Signal Transduct. Target. Ther.* **2020**, *5*, 1–23. [[CrossRef](#)] [[PubMed](#)]
113. Scannell, J.W.; Blanckley, A.; Boldon, H.; Warrington, B. Diagnosing the decline in pharmaceutical R&D efficiency. *Nat. Rev. Drug Discov.* **2012**, *11*, 191–200. [[CrossRef](#)] [[PubMed](#)]
114. Spreafico, R.; Soriaga, L.B.; Grosse, J.; Virgin, H.W.; Telenti, A. Advances in Genomics for Drug Development. *Genes* **2020**, *11*, 942. [[CrossRef](#)] [[PubMed](#)]
115. Aschenbrenner, D.S. Two New Drugs for Sickle Cell Disease. *Am. J. Nurs.* **2020**, *120*, 24. [[CrossRef](#)]
116. Ataga, K.I.; Kutlar, A.; Kanter, J.; Liles, D.; Cancado, R.; Friedrisch, J.; Guthrie, T.H.; Knight-Madden, J.; Alvarez, O.A.; Gordeuk, V.R.; et al. Crizanlizumab for the Prevention of Pain Crises in Sickle Cell Disease. *N. Engl. J. Med.* **2017**, *376*, 429–439. [[CrossRef](#)]
117. Vichinsky, E.; Hoppe, C.C.; Ataga, K.I.; Ware, R.E.; Nduba, V.; El-Beshlawy, A.; Hassab, H.; Achebe, M.M.; Al Kindi, S.; Brown, R.C.; et al. A Phase 3 Randomized Trial of Voxelotor in Sickle Cell Disease. *N. Engl. J. Med.* **2019**, *381*, 509–519. [[CrossRef](#)]
118. Sebastiani, P.; Solovieff, N.; Hartley, S.W.; Milton, J.N.; Riva, A.; Dworkis, D.A.; Melista, E.; Klings, E.; Garrett, M.E.; Telen, M.J.; et al. Genetic modifiers of the severity of sickle cell anemia identified through a genome-wide association study. *Am. J. Hematol.* **2010**, *85*, 29–35. [[CrossRef](#)]
119. Esrick, E.B.; Lehmann, L.E.; Biffi, A.; Achebe, M.; Brendel, C.; Ciuculescu, M.F.; Daley, H.; MacKinnon, B.; Morris, E.; Federico, A.; et al. Post-Transcriptional Genetic Silencing of BCL11A to Treat Sickle Cell Disease. *N. Engl. J. Med.* **2021**, *384*, 205–215. [[CrossRef](#)]
120. Cavazzana, M.; Payen, E.; Negre, O.; Wang, G.; Hehir, K.; Fusil, F.; Down, J.; Denaro, M.; Brady, T.; Westerman, K.; et al. Transfusion independence and HMGA2 activation after gene therapy of human beta-thalassaemia. *Nature* **2010**, *467*, 318–322. [[CrossRef](#)]
121. Stoica, L.; Sena-Esteves, M. Adeno Associated Viral Vector Delivered RNAi for Gene Therapy of SOD1 Amyotrophic Lateral Sclerosis. *Front. Mol. Neurosci.* **2016**, *9*, 56. [[CrossRef](#)] [[PubMed](#)]
122. Shibata, S.B.; Ranum, P.T.; Moteki, H.; Pan, B.; Goodwin, A.T.; Goodman, S.S.; Abbas, P.J.; Holt, J.R.; Smith, R.J.; Shibata, S.B.; et al. RNA Interference Prevents Autosomal-Dominant Hearing Loss. *Am. J. Hum. Genet.* **2016**, *98*, 1101–1113. [[CrossRef](#)] [[PubMed](#)]
123. Nathwani, A.C.; Reiss, U.M.; Tuddenham, E.G.; Rosales, C.; Chowdary, P.; McIntosh, J.; Della Peruta, M.; Lheriteau, E.; Patel, N.; Raj, D.; et al. Long-term safety and efficacy of factor IX gene therapy in hemophilia B. *N. Engl. J. Med.* **2014**, *371*, 1994–2004. [[CrossRef](#)] [[PubMed](#)]
124. Batty, P.; Lillicrap, D. Hemophilia Gene Therapy: Approaching the First Licensed Product. *Hemasphere* **2021**, *5*, e540. [[CrossRef](#)] [[PubMed](#)]
125. Hauswirth, W.; Aleman, T.S.; Kaushal, S.; Cideciyan, A.V.; Schwartz, S.B.; Wang, L.; Conlon, T.J.; Boye, S.L.; Flotte, T.R.; Byrne, B.J.; et al. Treatment of leber congenital amaurosis due to RPE65 mutations by ocular subretinal injection of adeno-associated virus gene vector: Short-term results of a phase I trial. *Hum. Gene Ther.* **2008**, *19*, 979–990. [[CrossRef](#)]
126. Maguire, A.M.; High, K.A.; Auricchio, A.; Wright, J.F.; Pierce, E.A.; Testa, F.; Mingozzi, F.; Bennicelli, J.L.; Ying, G.-S.; Rossi, S.; et al. Age-dependent effects of RPE65 gene therapy for Leber’s congenital amaurosis: A phase 1 dose-escalation trial. *Lancet* **2009**, *374*, 1597–1605. [[CrossRef](#)]
127. Bainbridge, J.W.; Mehat, M.S.; Sundaram, V.; Robbie, S.J.; Barker, S.E.; Ripamonti, C.; Georgiadis, A.; Mowat, F.; Beattie, S.G.; Gardner, P.; et al. Long-term effect of gene therapy on Leber’s congenital amaurosis. *N. Engl. J. Med.* **2015**, *372*, 1887–1897. [[CrossRef](#)]
128. Wright, A.F. Long-term effects of retinal gene therapy in childhood blindness. *N. Engl. J. Med.* **2015**, *372*, 1954–1955. [[CrossRef](#)]
129. Bennett, J.; Wellman, J.; Marshall, K.A.; McCague, S.; Ashtari, M.; DiStefano-Pappas, J.; Elci, O.U.; Chung, D.C.; Sun, J.; Wright, J.F.; et al. Safety and durability of effect of contralateral-eye administration of AAV2 gene therapy in patients with childhood-onset blindness caused by RPE65 mutations: A follow-on phase 1 trial. *Lancet* **2016**, *388*, 661–672. [[CrossRef](#)]
130. Mendell, J.R.; Al-Zaidy, S.; Shell, R.; Arnold, W.D.; Rodino-Klapac, L.R.; Prior, T.W.; Lowes, L.; Alfano, L.; Berry, K.; Church, K.; et al. Single-Dose Gene-Replacement Therapy for Spinal Muscular Atrophy. *N. Engl. J. Med.* **2017**, *377*, 1713–1722. [[CrossRef](#)]
131. Griesenbach, U.; Pytel, K.M.; Alton, E.W. Cystic Fibrosis Gene Therapy in the UK and Elsewhere. *Hum. Gene Ther.* **2015**, *26*, 266–275. [[CrossRef](#)] [[PubMed](#)]
132. U.S. Food and Drug Administration. Approved Cellular and Gene Therapy Products. Available online: <https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/approved-cellular-and-gene-therapy-products> (accessed on 26 October 2021).

133. U.S. Food and Drug Administration. ABECMA (Idecabtagene Vicleucel). Available online: <https://www.fda.gov/vaccines-blood-biologics/abecma-idecabtagene-vicleucel> (accessed on 21 April 2021).
134. U.S. Food and Drug Administration. BREYANZI (Lisocabtagene Maraleucel). Available online: <https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/breyanzi-lisocabtagene-maraleucel> (accessed on 4 March 2021).
135. U.S. Food and Drug Administration. IMLYGIC. Available online: <https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/imlygic> (accessed on 9 December 2021).
136. U.S. Food and Drug Administration. KYMRIAH (Tisagenlecleucel). Available online: <https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/kymriah-tisagenlecleucel> (accessed on 14 June 2021).
137. U.S. Food and Drug Administration. LUXTURNA. Available online: <https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/luxturna> (accessed on 26 July 2018).
138. U.S. Food and Drug Administration. PROVENGE (sipuleucel-T). Available online: <https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/provenge-sipuleucel-t> (accessed on 28 May 2019).
139. U.S. Food and Drug Administration. TECARTUS (Brexucabtagene Autoleucel). Available online: <https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/tecartus-brexucabtagene-autoleucel> (accessed on 17 November 2021).
140. U.S. Food and Drug Administration. YESCARTA (Axicabtagene Ciloleucel). Available online: <https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/yescarta-axicabtagene-ciloleucel> (accessed on 11 May 2021).
141. U.S. Food and Drug Administration. ZOLGENSMA. Available online: <https://www.fda.gov/vaccines-blood-biologics/zolgensma> (accessed on 26 October 2021).
142. Roden, D.M.; Wilke, R.A.; Kroemer, H.K.; Stein, C.M. Pharmacogenomics: The genetics of variable drug responses. *Circulation* **2011**, *123*, 1661–1670. [[CrossRef](#)] [[PubMed](#)]
143. Schärfe, C.P.I.; Tremmel, R.; Schwab, M.; Kohlbacher, O.; Marks, D.S. Genetic variation in human drug-related genes. *Genome Med.* **2017**, *9*, 117. [[CrossRef](#)] [[PubMed](#)]
144. Aneesh, T.P.; Sekhar, M.S.; Jose, A.; Chandran, L.; Zachariaha, S.M. Pharmacogenomics: The right drug to the right person. *J. Clin. Med. Res.* **2009**, *1*, 191–194. [[CrossRef](#)]
145. Hasin, Y.; Seldin, M.; Lusis, A. Multi-omics approaches to disease. *Genome Biol.* **2017**, *18*, 83. [[CrossRef](#)] [[PubMed](#)]
146. Cobain, E.F.; Wu, Y.-M.; Vats, P.; Chugh, R.; Worden, F.; Smith, D.C.; Schuetze, S.M.; Zalupski, M.M.; Sahai, V.; Alva, A.; et al. Assessment of Clinical Benefit of Integrative Genomic Profiling in Advanced Solid Tumors. *JAMA Oncol.* **2021**, *7*, 525–533. [[CrossRef](#)]
147. Relling, M.V.; Evans, W.E. Pharmacogenomics in the clinic. *Nature* **2015**, *526*, 343–350. [[CrossRef](#)]
148. Köhler, S.; Doelken, S.C.; Mungall, C.J.; Bauer, S.; Firth, H.V.; Bailleul-Forestier, I.; Black, G.C.M.; Brown, D.L.; Brudno, M.; Campbell, J.; et al. The Human Phenotype Ontology project: Linking molecular biology and disease through phenotype data. *Nucleic Acids Res.* **2014**, *42*, D966–D974. [[CrossRef](#)]
149. Köhler, S.; Gargano, M.; Matentzoglou, N.; Carmody, L.C.; Lewis-Smith, D.; Vasilevsky, N.A.; Danis, D.; Balagura, G.; Baynam, G.; Brower, A.M.; et al. The Human Phenotype Ontology in 2021. *Nucleic Acids Res.* **2021**, *49*, D1207–D1217. [[CrossRef](#)]
150. Hwang, T.; Atluri, G.; Xie, M.; Dey, S.; Hong, C.; Kumar, V.; Kuang, R. Co-clustering phenome-genome for phenotype classification and disease gene discovery. *Nucleic Acids Res.* **2012**, *40*, e146. [[CrossRef](#)]
151. Sánchez-Rico, M.; Alvarado, J.M. A Machine Learning Approach for Studying the Comorbidities of Complex Diagnoses. *Behav. Sci.* **2019**, *9*, 122. [[CrossRef](#)] [[PubMed](#)]
152. Narita, A.; Nagai, M.; Mizuno, S.; Ogishima, S.; Tamiya, G.; Ueki, M.; Sakurai, R.; Makino, S.; Obara, T.; Ishikuro, M.; et al. Clustering by phenotype and genome-wide association study in autism. *Transl. Psychiatry* **2020**, *10*, 290. [[CrossRef](#)] [[PubMed](#)]
153. Westbury, S.K.; on behalf of the BRIDGE-BPD Consortium; Turro, E.; Greene, D.; Lentaigne, C.; Kelly, A.M.; Bariana, T.K.; Simeoni, I.; Pillois, X.; Attwood, A.; et al. Human phenotype ontology annotation and cluster analysis to unravel genetic defects in 707 cases with unexplained bleeding and platelet disorders. *Genome Med.* **2015**, *7*, 36. [[CrossRef](#)] [[PubMed](#)]
154. Ashley, E.A. Towards precision medicine. *Nat. Rev. Genet.* **2016**, *17*, 507–522. [[CrossRef](#)]